Touchlight is an innovation-driven leading CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing already accepted in 2022, our enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and in vivo gene editing innovation. With multiple client products already in the clinic, our evidence-based, data-supported synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. Our company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, our team is inspired by breakthroughs in genome sequencing, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies. To address these challenges, we developed our first novel synthetic DNA vector, dbDNA™, alongside a proprietary enzymatic manufacturing process. This groundbreaking approach enables the production of complex DNA sequences with remarkable speed, scale, and purity, surpassing the limitations of traditional pDNA production while transforming the economics of bringing these therapies to market more efficiently and sustainably. Touchlight’s commitment to innovation is continually fueling product improvements and new product development. As of early 2024, we have partnered with hundreds of biotech and top 10 pharmaceutical companies, producing synthetic DNA for use as both a starting material and an active pharmaceutical ingredient. By the end of this year, dbDNA™ will be one of multiple synthetic DNA products in our portfolio that will continue to pave the way for more accessible cell and gene therapies.
External link for Touchlight
Hampton, London, England TW12 2ER, GB
Morelands & Riverdale Buildings,
Lower Sunbury Road,
Hampton, England TW12 2ER, GB
Morelands & Riverdale Buildings,
Lower Sunbury Road,
Hampton, TW12 2ER, GB
Touchlight reposted this
By moving away from restrictive biological approaches and instead using enzyme biochemistry, we are making DNA simple – we have eliminated the need for bacterial sequences, including antibiotic resistance genes. Learn more: https://lnkd.in/e8meAqY #biotechnology #pharma #biotech #genetherapy #dbDNA
We're hiring an Accountant! Work with a team that is changing science and enabling the next generation of genetic medicines. Find out more: https://lnkd.in/evQkkKv3 #biotechnology #pharma #biotech #genetherapy
By moving away from restrictive biological approaches and instead using enzyme biochemistry, we are making DNA simple – we have eliminated the need for bacterial sequences, including antibiotic resistance genes. Learn more: https://lnkd.in/e8meAqY #biotechnology #pharma #biotech #genetherapy #dbDNA
📢 It is exciting to announce that we are collaborating with LenioBio to accelerate the development of protein therapeutics for pandemic response. It is aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic dbDNA, to achieve unprecedented speed in vaccine development and manufacture in the context of LenioBio’s CEPI grant 🧬 🤝 Tommy Duncan, Ph.D. Touchlight's COO commented " We are delighted to be working with LenioBio to further demonstrate the breadth of dbDNA applications". Please click on the below link to read the full press release. 👉 https://lnkd.in/eCjFaiwG #Touchlight #Leniobio #dbDNA
Touchlight is pioneering the genetic medicine revolution with our novel dbDNA™ technology. As we push the boundaries of what's possible in DNA and mRNA therapies, gene editing, and more, we're curious to hear your thoughts! Cast your vote and join the conversation! Explore Touchlight: https://lnkd.in/g2-Pe8P #biotechnology #genetherapy #celltherapy #pharmaindustry
This content isn’t available here
Access this content and more in the LinkedIn app
🧬Here are the winners from our Touchlight Sports Day 2024! 🏅 It was a great afternoon for everyone at Touchlight, to spend time together and get a little competitive 🏃♀️ ⚾ 🍔🌭🍺 #Touchlight #SportsDay2024 #Winners #dbDNA https://lnkd.in/g2-Pe8P
dbDNA™ technology represents a significant leap toward making gene therapies more affordable, addressing both the efficacy and economic challenges that have historically hindered broader application. By enhancing AAV packaging efficiency, we can ensure a higher proportion of viral vectors correctly carry the intended DNA sequence. This improvement in particle quality is crucial for developing safe, effective therapies. Moreover, dbDNA™ significantly cuts the per-dose production costs. By streamlining the manufacturing process, Touchlight not only speeds up the development of AAV-based therapeutics but also makes these potentially life-saving treatments more accessible and affordable. Explore how Touchlight is contributing to a future where advanced therapies are within reach for more patients: https://lnkd.in/e4K-gx4H Tom Merritt #genetherapy #biotech #pharma #advancedtherapies
At Touchlight, our proprietary dbDNA™ technology is setting new standards for how genetic medicines are developed. Capable of producing GMP DNA at unprecedented speed and scale, dbDNA™ supports the rapid development of cell and gene therapies. Enzymatic production eliminates bacterial sequences, enhancing safety and efficacy. Watch our video for a closer look. Explore the transformative potential of dbDNA™: https://lnkd.in/e8meAqY #biotechnology #pharma #biotech #genetherapy
In case you missed it — the Touchlight team hosted a webinar in collaboration with Genetic Engineering & Biotechnology News on the groundbreaking potential of nucleic acid vaccination in the field of immune oncology. This advanced method offers a more personalised approach to cancer treatment, tailoring therapies to the unique genetic makeup of a patient’s tumour, thus minimising risks and enhancing precision. During the session, Touchlight's Lisa Caproni, PhD and Pierre MARSCHALL of Odimma Therapeutics delved into the innovative use of Touchlight's proprietary dbDNA™ in developing a cutting-edge neoantigen with Odimma Therapeutics, highlighting the potential of dbDNA™ in optimising development and manufacturing processes for personalised cancer treatments, as well as mRNA vaccines, gene therapies, and beyond. Missed the webinar? Watch the full recording here: https://lnkd.in/ezmkifi6 #biotechnology #pharmaindustry #pharma #genetherapy
Our clinically validated dbDNA™ technology offers unmatched efficiency in AAV vector production and improved empty:full capsid ratios. With the ability to efficiently manufacture complex sequences, including ITRs, dbDNA™ not only facilitates the production of a wide array of viral vectors but also ensures high fidelity and minimal contamination risks. Ready-to-use research-grade dbDNA™ accelerates evaluations, with both research- and GMP-grade dbDNA available on accelerated timelines. Read more in our latest article: https://lnkd.in/e4K-gx4H Tom Merritt #genetherapy #biotech #advancedtherapies #pharmaindustry